Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Blood Adv 2024 Aug 13;8(15):4164-4168
Date
06/25/2024Pubmed ID
38916857Pubmed Central ID
PMC11334869DOI
10.1182/bloodadvances.2024012928Scopus ID
2-s2.0-85201500415 (requires institutional sign-in at Scopus site) 4 CitationsAuthor List
Bender JD, Damodharan S, Capitini CM, Moskop A, Toner K, Vatsayan A, Talano JA, Baggott C, Schiff D, Katsanis E, Modi AJ, Quigg TC, Raikar SS, Schultz LM, Pommert LAuthors
Amy Moskop MD Associate Professor in the Pediatrics department at Medical College of WisconsinJulie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdolescentAdult
Child
Child, Preschool
Female
Humans
Immunotherapy, Adoptive
Lymphoma, B-Cell
Male
Receptors, Antigen, T-Cell
Recurrence
Treatment Outcome
Young Adult









